Showing 1601-1610 of 9707 results for "".
New Treatment Algorithms for Actinic Keratoses
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-treatment-algorithms-for-actinic-keratoses/18812/Gary Goldenberg, MD reviews the literature showing why all actinic keratoses (AKs) need to be treated and why it's important to treat the field and not just the visible lesions. He shares his evidence-based, time-sequential therapy approach to combining a destructive modality with field therapy to pLong-Term Effects of Neuromodulators on Aging
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/long-term-effects-of-neuromodulators-on-aging/18810/Shannon Humphrey, MD discusses the cumulative anti-aging benefits of long-term treatments with botulinum toxin type A. She shares her observations from the bench and offers a review of what the literature shows to support her recommendation for regular conservative neuromodulator treatments to improAdvances in Devices for Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-devices-for-dermatology/18815/M. Christine Lee, MD provides an overview of some of the new and emerging laser technologies. She discusses advances in everything from lasers and light-based devices to radiofrequency, ultrasound, and combination devices for a variety of dermatologic issues including facial rejuvenation, vaginal reHerbals in the Holistic Treatment of Psoriasis
https://practicaldermatology.com/topics/psoriasis/herbals-in-the-holistic-treatment-of-psoriasis/21055/Dermatologists must be aware of the herbal supplements patients may take and their potential effects.Risks of Multiple Primary Melanomas
https://practicaldermatology.com/topics/practice-management/risks-of-multiple-primary-melanomas/21058/Studies offer clarity on risks and patterns after diagnosis, as well as survival outcomes.The Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availThe Evolving Paradigm in Treatment of Psoriasis
https://practicaldermatology.com/topics/psoriasis/the-evolving-paradigm-in-treatment-of-psoriasis/18640/Bruce Strober, MD, reviews the latest science in the management of psoriasis. Treatment strategies on the horizon may offer significantly improved efficacy with attractive dosing schedules, adding to the ability to help patients manage difficult skin and systemic implications of psoriasis, he said.The Art of Medicine in the Age of Technology
https://practicaldermatology.com/topics/practice-management/the-art-of-medicine-in-the-age-of-technology/21065/Although electronic technology offers potential for a more efficient delivery of healthcare, the patient experience may suffer as a result.Currents: Use as Directed
https://practicaldermatology.com/topics/psoriasis/currents-use-as-directed/21082/Strategies to improve outcomes and enhance adherence in psoriasis, acne, eczema, and aestheticsI knew I wanted to become a dermatologist when...
https://practicaldermatology.com/topics/practice-management/i-knew-i-wanted-to-become-a-dermatologist-when---opefutim/18682/PD Asks: When Yolanda Lenzy, MD was about 13 years old she visited the office of Dr. Lynn McKinley Grant in Washington, DC. It was her first experience with an African American physician, and Dr. Lenzy describes how Dr. McKinley Grant inspired and supported her aspirations. Watch other responses to